Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in...